Qelbree Titration: What the Viloxazine Label Says
The Qelbree label's starting doses, weekly steps and maximums by age, what its studies say about time to effect, the boxed warning, and what to log.
Get new titration guides by email
Occasional, evidence-based guides on medication tracking and titration — no noise.
Disclaimer: This article is for education only. It is not medical advice, a diagnosis, or a dose recommendation. The numbers below are the starting points and limits printed on the US label. Your prescriber adapts them to you and may choose a different schedule. Never change how you take a medicine without talking to them first.
What Qelbree is
Qelbree is the brand name for viloxazine extended-release capsules. It is a non-stimulant, which the label describes as a selective norepinephrine reuptake inhibitor, and it is approved in the US for ADHD in adults and in children aged 6 and older [1]. It is taken once a day.
People starting Qelbree usually want to know two things: how the dose is built up, and how long it takes before they can tell whether it is working. This guide sets out what the label says on both, and what is worth logging while it happens. All figures come from the FDA prescribing information on DailyMed.
Read this first: the boxed warning
Qelbree carries a boxed warning, the strongest kind on a US label. In clinical studies, higher rates of suicidal thoughts and behaviors were reported in people with ADHD taking Qelbree than in people taking placebo [1]. Among children and teenagers in short-term studies, 0.9% on Qelbree reported suicidal thoughts or behavior compared with 0.4% on placebo. Among adults, 1.6% reported suicidal thoughts compared with none on placebo [1].
The label asks for close monitoring, especially in the first few months and whenever the dose goes up or down [1]. It also lists changes that may come before those thoughts, including insomnia, irritability, depressed mood, anxiety, agitation, panic attacks, impulsive behavior and aggression [1].
If you or your child has thoughts of self-harm or suicide, or a sudden change in mood or behavior, contact your doctor straight away. If you are in immediate danger, call emergency services or go to urgent care.
The label's titration schedule
The label gives a starting dose, a step size, a step interval and a maximum for each age group. It says the dose may be adjusted "depending on response and tolerability", which is the prescriber's call [1].
| Group | Label starting dose | Label step | Label maximum |
|---|---|---|---|
| Children 6 to 11 | 100 mg once daily | Up by 100 mg at weekly intervals | 400 mg once daily [1] |
| Teenagers 12 to 17 | 200 mg once daily | After 1 week, up by one 200 mg step | 400 mg once daily [1] |
| Adults | 200 mg once daily | Up by 200 mg weekly | 600 mg once daily [1] |
| Severe kidney impairment | 100 mg once daily | Weekly steps of 50 to 100 mg | 200 mg once daily [1] |
These are the label's numbers, and your own schedule may look different. A prescriber may move more slowly, hold at a dose for longer or stop at a lower dose that works. The label also asks for heart rate and blood pressure to be checked before starting, after each dose increase and from time to time during treatment [1].
How long until you can tell it is working
The label does not give a week-by-week timeline for when Qelbree starts to help. What it does describe is how long the clinical studies ran and when the result was measured:
| Study group | Total length | Titration period | When the main result was measured |
|---|---|---|---|
| Children 6 to 11 (first study) | 6 weeks | 1 week | End of study [1] |
| Children 6 to 11 (second study) | 8 weeks | 3 weeks | End of study [1] |
| Teenagers 12 to 17 | 6 weeks | 1 week | End of study [1] |
| Adults | 6 weeks | Dose adjusted weekly between 200 and 600 mg | End of study [1] |
In the adult study, the average dose by the end was 504 mg a day [1]. So the evidence on the label is a result measured after six to eight weeks, not a promise of a specific week when you will notice a change. If you have read that non-stimulants take several weeks, the non-stimulant ADHD medications guide covers that across the class.
The label also says blood levels of viloxazine reach a steady state after two days of once-daily dosing [1]. That is about the level of medicine in the blood, and it doesn't tell you when symptoms will change.
Taking it
The label says Qelbree can be taken with or without food [1]. A high-fat meal lowered the peak level by about 9% and the total absorbed by about 8%, and moved the peak about 2 hours later [1]. After a single dose, the peak typically came about 5 hours after the dose, with a range of 3 to 9 hours, and the average half-life was about 7 hours [1].
The capsule can be swallowed whole, or opened and the whole contents sprinkled over a teaspoon or tablespoon of applesauce or pudding. The mixture should be eaten without chewing, within 15 minutes if it is pudding or within 2 hours if it is applesauce, and not stored [1]. The capsule shouldn't be cut, crushed or chewed [1].
Qelbree must not be taken with an MAOI or within 2 weeks of stopping one [1]. It also strongly blocks an enzyme called CYP1A2, which some other medicines rely on, so tell your prescriber and pharmacist about everything else you take [1].
Side effects the label reports
In the adult study, the most common side effects were insomnia, headache, sleepiness, fatigue, nausea, decreased appetite, dry mouth and constipation [1]. Insomnia was reported by 23% of adults on Qelbree compared with 7% on placebo. Sleepiness was reported by 6% compared with 2%, and fatigue by 12% compared with 3% [1]. In children and teenagers, sleepiness was more common, at 16% compared with 4% on placebo [1].
Heart rate went up in some people. In the adult study, 29% on Qelbree had an increase of 20 beats per minute or more at some point, compared with 13% on placebo [1]. The label asks people to be careful driving or using machinery until they know how Qelbree affects them, because of the sleepiness and fatigue [1].
If you are comparing Qelbree with atomoxetine, the atomoxetine titration guide covers that medicine in the same way.
What to log and show your prescriber
Qelbree's dose is often adjusted week by week, and the label asks for close monitoring of mood at exactly those points. A daily log makes each review much easier.
| What to log | Why it helps |
|---|---|
| Dose and the time you took it | Shows which week of titration each entry belongs to |
| A focus or "how the day went" score, 1 to 5 | Shows whether things change over the weeks |
| Mood, irritability and anxiety | The label asks for close watching, especially after dose changes |
| Sleep, including trouble falling asleep and daytime sleepiness | Insomnia, sleepiness and fatigue were all common |
| Heart rate and blood pressure, if you have a home monitor | The label asks for checks after each dose increase |
| Appetite and nausea | Both were among the common side effects |
At each review, a short summary works well, something like "week 3 at the new dose, focus slightly better, falling asleep later." Titrate records dose changes and daily check-ins with one tap and builds a dated report, and the medication review appointment guide covers what to bring.
Don't raise, lower or stop your dose based on what you find. Share it, and let your prescriber decide.
If you have thoughts of self-harm or suicide, chest pain, a racing heart that doesn't settle, fainting or signs of mania, contact your doctor or urgent care right away.
Key takeaways
- Qelbree (viloxazine) is a once-daily non-stimulant approved for ADHD in adults and children aged 6 and older.
- It carries a boxed warning about suicidal thoughts and behaviors, and the label asks for close monitoring early on and at every dose change.
- The label's adult schedule starts at 200 mg once daily and allows weekly 200 mg steps up to 600 mg, but your prescriber sets the actual pace.
- The label doesn't give a week-by-week timeline to effect. Its studies measured results after 6 to 8 weeks.
- Log mood, sleep and heart rate alongside each dose change and bring the record to your prescriber.
FAQ
Q: What is the starting dose of Qelbree? The label lists 200 mg once daily for adults and teenagers aged 12 to 17, and 100 mg once daily for children aged 6 to 11. People with severe kidney impairment start at 100 mg. These are the label's starting points, and your prescriber decides what fits you.
Q: How fast is Qelbree titrated? The label allows weekly steps: 200 mg for adults up to 600 mg, 100 mg for children aged 6 to 11 up to 400 mg, and one 200 mg step after a week for teenagers up to 400 mg. The label ties every step to response and tolerability, and your prescriber may move more slowly.
Q: How long does Qelbree take to work? The label doesn't give a specific timeline. Its studies lasted 6 to 8 weeks, including 1 to 3 weeks of titration, and measured the main result at the end. Logging focus and side effects each week helps you and your prescriber see whether it is helping.
Q: Does Qelbree cause insomnia or sleepiness? It can cause both. In the adult study, insomnia was reported by 23% on Qelbree compared with 7% on placebo, and sleepiness by 6% compared with 2%. Note when you take it and how you sleep, and talk to your prescriber before changing anything.
Q: Can I open Qelbree capsules? Yes. The label allows the capsule to be opened and sprinkled over applesauce or pudding, eaten without chewing, within 15 minutes for pudding or 2 hours for applesauce. The capsule shouldn't be cut, crushed or chewed.
Q: What does the Qelbree boxed warning mean? In studies, suicidal thoughts and behaviors were reported more often with Qelbree than with placebo. The label asks for close monitoring, especially in the first few months and after any dose change. If you notice thoughts of self-harm or a sudden change in mood, contact your doctor straight away or go to urgent care.
References
- FDA prescribing information — Qelbree (viloxazine extended-release capsules), boxed warning and sections 1, 2, 4, 5, 6, 7, 12.3 and 14, DailyMed
This article is for educational purposes only. It does not constitute medical advice. Always consult your licensed healthcare provider about medication decisions.